[VRML] Vermillion, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.05 Change: 0.02 (1.94%)
Ext. hours: Change: 0 (0%)

chart VRML

Refresh chart

Strongest Trends Summary For VRML

VRML is in the medium-term up 66% above S&P in 3 months. In the long-term down -52% in 1 year and down -67% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Vermillion, Inc., together with its subsidiaries, is engaged in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. It develops diagnostic tests in the fields of oncology and women?s health. The company?s lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was founded in 1993 and is headquartered in Austin, Texas.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 193.52% Sales Growth - Q/Q-39.39% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-103.66% ROE-127.45% ROI
Current Ratio5.19 Quick Ratio Long Term Debt/Equity Debt Ratio0.23
Gross Margin47.4% Operating Margin-615.03% Net Profit Margin-611.27% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.16 M Cash From Investing Activities-40 K Cash From Operating Activities-4.53 M Gross Profit460 K
Net Profit-4.14 M Operating Profit-4.26 M Total Assets18.68 M Total Current Assets18.09 M
Total Current Liabilities3.48 M Total Debt Total Liabilities3.48 M Total Revenue950 K
Technical Data
High 52 week1.58 Low 52 week0.29 Last close0.71 Last change-5.62%
RSI39.63 Average true range0.08 Beta0.59 Volume32.31 K
Simple moving average 20 days-5.07% Simple moving average 50 days17.65% Simple moving average 200 days4.52%
Performance Data
Performance Week-11.88% Performance Month-3.42% Performance Quart42.48% Performance Half21.55%
Performance Year-48.16% Performance Year-to-date135% Volatility daily4.9% Volatility weekly10.96%
Volatility monthly22.46% Volatility yearly77.82% Relative Volume196.24% Average Volume144.55 K
New High New Low

News

2019-03-12 12:27:40 | Vermillion to Report Fourth Quarter and Year End 2018 Financial Results on Thursday, March 28

2019-01-22 12:46:47 | Could Vermillion, Inc.’s NASDAQ:VRML Investor Composition Influence The Stock Price?

2019-01-15 09:46:46 | Vermillion Announces Coverage by Cigna for OVA1® MIA

2018-12-14 13:24:01 | What Investors Should Know About Vermillion, Inc.’s NASDAQ:VRML Financial Strength

2018-11-20 16:01:00 | Vermillion to Present at the Piper Jaffray 30th Annual Healthcare Conference

2018-11-14 08:00:00 | New Research Coverage Highlights Nexa Resources S.A, Qumu, Clearway Energy, Vermillion, Cantel Medical, and Theravance Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-12 08:00:00 | Vermillion to Present at the Canaccord Medical Technology & Diagnostics Forum

2018-11-09 12:16:36 | Is Vermillion Inc’s NASDAQ:VRML CEO Salary Justified?

2018-11-09 09:27:52 | Edited Transcript of VRML earnings conference call or presentation 8-Nov-18 9:30pm GMT

2018-11-08 17:12:48 | Vermillion: 3Q Earnings Snapshot

2018-11-08 16:01:00 | Vermillion Announces OVA1® MIA and OVERA® MIA2G Study and Coverage by Clalit Health Services in Israel

2018-11-08 16:01:00 | Vermillion Reports Third Quarter 2018 Financial Results

2018-10-26 16:05:00 | Vermillion to Report Third Quarter and Nine Months Ended September 30, 2018 Financial Results on Thursday, November 8

2018-10-09 08:00:00 | Vermillion, Inc. Announces the Launch of OVA1®+

2018-09-06 09:00:00 | Vermillion, Inc. Kicks Off Ovarian Cancer Awareness Month by Ringing the NASDAQ Closing Bell

2018-08-26 19:45:45 | Edited Transcript of VRML earnings conference call or presentation 9-Aug-18 8:30pm GMT

2018-08-21 16:01:00 | Vermillion, Inc. Appoints Nancy Cocozza to its Board of Directors

2018-08-09 17:07:21 | Vermillion: 2Q Earnings Snapshot

2018-08-09 16:01:00 | Vermillion Reports Second Quarter 2018 Financial Results

2018-07-18 08:00:00 | Vermillion to Report Second Quarter and Six Months Ended June 30, 2018 Financial Results on Thursday, August 9

2018-06-26 11:56:44 | Analysts Expect Breakeven For Vermillion Inc NASDAQ:VRML

2018-06-13 11:08:18 | Vermillion Names Chris Goulart to Senior Vice President of Commercial Operations

2018-06-04 20:58:21 | At $1, Is Vermillion Inc NASDAQ:VRML A Buy?

2018-05-14 21:41:53 | Edited Transcript of VRML earnings conference call or presentation 14-May-18 8:30pm GMT

2018-05-14 16:44:15 | Vermillion: 1Q Earnings Snapshot

2018-05-14 16:01:00 | Vermillion Reports First Quarter 2017 Financial Results

2018-05-14 12:45:00 | Vermillion, Inc. to Host Earnings Call

2018-05-03 16:01:00 | Vermillion to Report First Quarter 2018 Financial Results on Monday, May 14

2018-04-26 08:00:00 | Vermillion Announces Recognition by and Publication in Two Top Physician Educational Resources

2018-04-13 09:17:35 | Vermillion, Inc. Announces Pricing of $15 Million Concurrent Public Offerings of Common Stock and Preferred Stock

2018-04-12 16:44:31 | Vermillion, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

2018-04-04 12:31:14 | Vermillion Inc NASDAQ:VRML: Immense Growth Potential?

2018-03-23 14:28:16 | Did Vermillion Inc’s NASDAQ:VRML Recent Earnings Growth Beat The Trend?

2018-03-14 13:16:24 | Edited Transcript of VRML earnings conference call or presentation 13-Mar-18 8:30pm GMT

2018-03-13 16:19:28 | Vermillion reports 4Q loss

2018-03-13 16:01:00 | Vermillion Reports Fourth Quarter and Fiscal Year 2017 Financial Results

2018-03-13 12:00:00 | Vermillion, Inc. to Host Earnings Call

2018-03-07 16:01:00 | Vermillion to Present at the 30th Annual ROTH Conference

2018-02-28 08:00:00 | Vermillion to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Tuesday, March 13

2018-02-23 08:00:00 | Vermillion to Present at the 2018 BTIG Healthcare Conference

2018-02-19 18:11:15 | What Is Vermillion Inc’s NASDAQ:VRML Share Price Doing?

2018-02-05 08:45:00 | Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents

2018-01-18 08:45:00 | Vermillion Announces Agreement with BlueCross BlueShield of Illinois

2018-01-01 09:13:39 | Vermillion, Inc. :VRML-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018

2017-12-26 19:05:09 | Are Vermillion Inc’s NASDAQ:VRML Interest Costs Too High?

2017-12-19 08:45:00 | Vermillion Appoints Bob Beechey to Newly Created CFO Post

2017-11-21 08:45:00 | Vermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference

2017-11-20 08:56:00 | ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1

2017-11-16 08:45:00 | Vermillion Announces Publication of Foundational Health Economics Study

2017-11-09 18:41:01 | Edited Transcript of VRML earnings conference call or presentation 8-Nov-17 9:30pm GMT